The better the antibiotic, the less you want to use it
In a Houston laboratory, researchers have found that a decades-old blood pressure medication may carry an unexpected weapon against one of modern medicine's most dangerous adversaries. Candesartan cilexetil, already trusted by millions for managing hypertension, appears capable of dismantling MRSA — a superbug that claims thousands of lives each year and embodies the slow unraveling of antibiotic medicine. The discovery reminds us that solutions to new crises sometimes lie hidden within the familiar, waiting for the right question to be asked.
- MRSA kills roughly 9,000 Americans annually and was part of a global toll of 1.27 million antibiotic-resistance deaths in 2019 — a crisis that has outpaced the pharmaceutical world's willingness to respond.
- A blood pressure drug already in millions of medicine cabinets has been found to punch holes in MRSA's cell membrane, killing both active and dormant bacteria — the hidden reservoir that makes the superbug so hard to eradicate.
- When paired with the existing antibiotic gentamicin, Candesartan cilexetil achieved stronger results at lower doses, suggesting a combination strategy that could sidestep the resistance problem rather than confront it head-on.
- Because the drug is already approved, inexpensive, and well-understood by regulators, it could reach patients far faster than any newly developed antibiotic — a rare shortcut in a field where shortcuts almost never exist.
- Researchers are now engineering modified versions of the compound and opening early talks with pharmaceutical companies, but the road from laboratory worms to human patients remains long and uncertain.
A team at Houston Methodist Research Institute in Texas has made an unexpected discovery: Candesartan cilexetil, a blood pressure medication prescribed for decades, appears to kill MRSA — the antibiotic-resistant superbug responsible for more than 70,000 severe infections and roughly 9,000 deaths each year in the United States alone. The findings were published in Nature Communications.
In laboratory and animal studies, the drug attacked MRSA by rupturing its cell membrane, causing the bacteria's contents to leak out and the cells to die. Crucially, it could also reach dormant bacteria — the hidden reservoirs that allow MRSA to resurface long after initial treatment. When combined with the antibiotic gentamicin, the effect was amplified at doses lower than either drug required alone.
The discovery emerged from a painstaking screen of more than 80,000 compounds tested on MRSA-infected worms. Only a handful showed promise, and the team spent years building a precise understanding of how Candesartan cilexetil interacts with bacterial membranes at the genetic and molecular level.
What gives the finding unusual weight is the drug's existing status: it is already approved, affordable, and widely used. Should human trials confirm its effectiveness, it could be deployed far more quickly than any newly developed antibiotic. Senior author Eleftherios Mylokanis noted the perverse economics that have long stalled antibiotic development — the better a drug works, the less it gets used, making it a poor investment for pharmaceutical companies.
Researchers are now developing chemically modified versions of the compound and are in early discussions with pharmaceutical and biotech partners about advancing toward clinical trials. As first author Nagendran Tharmalingam described it, the work of moving from benchside to bedside has only just begun.
A team of researchers at Houston Methodist Research Institute in Texas has stumbled onto something unexpected: a blood pressure medication sitting in millions of medicine cabinets might be capable of killing one of medicine's most intractable enemies. The drug is called Candesartan cilexetil. It's been prescribed for decades to manage high blood pressure and heart failure. And according to work published in Nature Communications, it appears to have a lethal effect on methicillin-resistant Staphylococcus aureus—MRSA—the superbug that has become a fixture of modern hospital infections and a symbol of how badly we've mismanaged our relationship with antibiotics.
In laboratory and animal studies, the researchers watched as Candesartan cilexetil attacked the bacteria in a surprisingly direct way. The drug punched holes in the MRSA cell membrane, using advanced imaging to reveal the damage in real time. Once those holes opened, the cell's contents leaked out. The bacteria died. What made this finding particularly significant was that the drug didn't just kill active MRSA cells—it could also target dormant bacteria hiding in the body, the kind that resurface later and make MRSA so difficult to eliminate completely. When the researchers combined Candesartan cilexetil with gentamicin, an existing antibiotic, the effect was stronger at lower doses than either drug alone.
The numbers that frame this discovery are sobering. In the United States alone, MRSA causes more than 70,000 severe infections each year and kills around 9,000 people. Globally, antibiotic-resistant bacteria were directly responsible for more than 1.27 million deaths in 2019. These aren't rare complications—they're a growing tide. Yet the development of new antibiotics has not kept pace with the threat, largely because pharmaceutical companies see limited profit in drugs designed to be used sparingly. As Eleftherios Mylokanis, an infectious disease specialist at Houston Methodist and senior author of the study, told reporters, the market logic is backwards: the better an antibiotic works, the less you want to use it, because you're trying to prevent resistance from developing.
The path to this discovery was methodical and long. The team screened more than 80,000 compounds on MRSA-infected worms. Only a handful showed promise. Candesartan cilexetil was among them. From there, the researchers spent considerable time building a detailed understanding of how the drug actually works against the bacteria—examining genetic material, lipids, and the small molecules involved in the interaction. Nagendran Tharmalingam, the study's first author, described the process as painstaking: building the picture one block at a time until they understood exactly how the drug was causing membrane injury.
What makes this finding potentially transformative is the drug's existing status. Candesartan cilexetil is already approved by regulators, already inexpensive, and already in widespread use. If its effectiveness against MRSA holds up in human trials, it could be deployed far more quickly than a newly developed antibiotic would be. The researchers are now working on chemically modified versions that might prove even more potent and carry fewer side effects. They're also in early conversations with pharmaceutical and biotech companies about advancing toward human testing. Mylokanis called Candesartan cilexetil one of the most exciting agents they've found. The next step is moving it from the laboratory bench to actual patients—from benchside to bedside, as Tharmalingam put it. That work has only just begun.
Citações Notáveis
One of the most exciting agents we have found— Eleftherios Mylokanis, infectious disease specialist at Houston Methodist
We are trying to get this from benchside to bedside— Nagendran Tharmalingam, first author of the study
A Conversa do Hearth Outra perspectiva sobre a história
Why does a blood pressure drug work against bacteria at all? That seems like it shouldn't.
It's not as strange as it sounds. The drug was designed to interact with human cell membranes in a specific way. MRSA's cell membrane, it turns out, has vulnerabilities that respond to the same mechanism. The drug doesn't know it's fighting bacteria—it just does what it does, and in this case, that's lethal to the bug.
But you tested 80,000 compounds. Why did this one stand out?
Because it actually worked. Most compounds do nothing. This one killed the bacteria in the lab and in infected animals. That's rare enough to matter.
The dormant bacteria angle—that's the part that seems genuinely new. Why is that so hard to treat normally?
Because antibiotics are designed to kill active, growing cells. Dormant bacteria are essentially in hibernation. They're not metabolizing, not dividing. Standard antibiotics can't touch them. Then the patient thinks they're cured, and months later the infection comes roaring back. This drug seems to damage the membrane even when the cell is dormant.
So why isn't this already in human trials?
Because lab results and animal studies are one thing. You have to prove it's safe and effective in people. And you have to convince companies it's worth the investment. The financial incentives in antibiotic development are broken—there's not enough money in it.
What happens if the modified versions work better?
Then you have a drug that's cheap, already approved, and genuinely effective against one of the bacteria we're most afraid of. That changes the calculus for treating MRSA infections.